Cyclopharm Ltd (ASX: CYC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cyclopharm Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cyclopharm Ltd (ASX: CYC)
Latest News
Share Market News
ASX shares vs. property: The opportunities in 2024
Share Gainers
Why CSL, Cyclopharm, Dicker Data, and Fletcher Building shares are pushing higher
Share Gainers
Can you guess the top 3 performing All Ordinaries shares in the first week of trade?
Share Gainers
Cyclopharm (ASX:CYC) share price jumps on trading update
Healthcare Shares
Why the Cyclopharm (ASX:CYC) share price is crashing 42% lower
Healthcare Shares
Why is the Cyclopharm (ASX:CYC) share price down today?
Share Market News
Why the Cyclopharm (ASX:CYC) share price popped 6% today
Share Market News
Why the Cyclopharma (ASX:CYC) share price surged to record high today
Speculative
Cyclopharm share price rockets 22% higher on FDA application approval
⏸️ Investing
3 speculative micro-cap shares that could make you a fortune
⏸️ Investing
3 cheap diversified micro-cap stocks for your portfolio
⏸️ Investing
10 stocks up by more than 50% in the past month
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
01 Sep 2023 | $0.0050 | 0.00% | Interim | 11 Sep 2023 |
27 Mar 2023 | $0.0050 | 0.00% | Final | 04 Apr 2023 |
02 Sep 2022 | $0.0050 | 0.00% | Interim | 12 Sep 2022 |
04 Apr 2022 | $0.0050 | 0.00% | Final | 12 Apr 2022 |
03 Sep 2021 | $0.0050 | 0.00% | Interim | 13 Sep 2021 |
01 Apr 2021 | $0.0050 | 0.00% | Final | 13 Apr 2021 |
04 Sep 2020 | $0.0050 | 0.00% | Interim | 14 Sep 2020 |
30 Mar 2020 | $0.0050 | 0.00% | Final | 07 Apr 2020 |
06 Sep 2019 | $0.0050 | 0.00% | Interim | 16 Sep 2019 |
05 Apr 2019 | $0.0050 | 0.00% | Final | 15 Apr 2019 |
07 Sep 2018 | $0.0050 | 0.00% | Interim | 17 Sep 2018 |
06 Apr 2018 | $0.0050 | 0.00% | Final | 16 Apr 2018 |
01 Sep 2017 | $0.0000 | 0.00% | Interim | 11 Sep 2017 |
31 Mar 2017 | $0.0050 | 0.00% | Final | 10 Apr 2017 |
02 Sep 2016 | $0.0050 | 46.00% | Interim | 12 Sep 2016 |
11 Apr 2016 | $0.0050 | 100.00% | Interim | 19 Apr 2016 |
CYC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Cyclopharm Ltd
Cyclopharm Ltd is a company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. It operates through the following segments. The Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism, and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment offers to produce radiopharmaceuticals tobe used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The firm generates maximum revenue from the Technegas segment.
CYC Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
27 Mar 2024 | $1.84 | $0.03 | 1.67% | 28,814 | $1.80 | $1.84 | $1.80 |
26 Mar 2024 | $1.80 | $-0.01 | -0.55% | 15,462 | $1.80 | $1.80 | $1.78 |
25 Mar 2024 | $1.82 | $0.01 | 0.56% | 5,318 | $1.80 | $1.82 | $1.78 |
22 Mar 2024 | $1.80 | $0.02 | 1.12% | 5,991 | $1.79 | $1.80 | $1.79 |
21 Mar 2024 | $1.78 | $-0.02 | -1.11% | 11,085 | $1.82 | $1.82 | $1.78 |
20 Mar 2024 | $1.80 | $0.02 | 1.12% | 5,268 | $1.78 | $1.83 | $1.78 |
19 Mar 2024 | $1.78 | $-0.02 | -1.11% | 19,333 | $1.80 | $1.81 | $1.78 |
18 Mar 2024 | $1.80 | $0.04 | 2.27% | 9,765 | $1.79 | $1.80 | $1.79 |
15 Mar 2024 | $1.77 | $-0.04 | -2.22% | 567 | $1.76 | $1.77 | $1.76 |
13 Mar 2024 | $1.80 | $0.04 | 2.27% | 10,683 | $1.78 | $1.80 | $1.76 |
12 Mar 2024 | $1.76 | $-0.01 | -0.56% | 15,531 | $1.77 | $1.77 | $1.76 |
11 Mar 2024 | $1.77 | $0.00 | 0.00% | 16,546 | $1.79 | $1.79 | $1.77 |
08 Mar 2024 | $1.77 | $0.00 | 0.00% | 1,746 | $1.80 | $1.81 | $1.77 |
07 Mar 2024 | $1.77 | $-0.03 | -1.67% | 15,449 | $1.80 | $1.82 | $1.77 |
06 Mar 2024 | $1.80 | $-0.03 | -1.64% | 18,757 | $1.82 | $1.82 | $1.78 |
05 Mar 2024 | $1.83 | $0.05 | 2.81% | 3,508 | $1.83 | $1.83 | $1.79 |
04 Mar 2024 | $1.78 | $-0.02 | -1.11% | 54,273 | $1.81 | $1.81 | $1.76 |
01 Mar 2024 | $1.80 | $0.00 | 0.00% | 8,766 | $1.81 | $1.81 | $1.79 |
29 Feb 2024 | $1.81 | $0.00 | 0.00% | 404,519 | $1.80 | $1.81 | $1.79 |
28 Feb 2024 | $1.81 | $0.00 | 0.00% | 32,822 | $1.82 | $1.82 | $1.80 |
27 Feb 2024 | $1.80 | $-0.09 | -4.77% | 35,361 | $1.79 | $1.83 | $1.78 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
30 Nov 2023 | James McBrayer | Buy | 200,000 | $262,000 |
Exercise of options. estimated value
|
30 Nov 2023 | James McBrayer | Exercise | 200,000 | $262,000 |
Exercise of options. estimated value
|
01 Nov 2023 | Kevin Barrow | Buy | 1,000 | $1,960 |
On-market trade.
|
31 Oct 2023 | David Heaney | Buy | 10,000 | $20,400 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr David James Heaney | Non-Executive DirectorNon-Executive Chairman | Nov 2006 |
Mr Heaney has more than 40 years experience in all aspects of wholesale banking and finance, gained in general management roles with National Australia Bank Limited and subsidiary companies in both Australia and the US.
|
Ms Dianne Margaret Angus | Non-Executive Director | Aug 2021 |
Ms Angus is currently a Non-Executive Director of ASX Listed Companies Imagion Biosystems Limited and Neuren Pharmaceuticals Limited. She has executive experience in the Biotechnology industry and has previously held senior positions with Prana Biotechnology Limited and Florigene Limited. Ms Angus also has expertise in corporate strategy, innovative product development, governance and compliance in the pharmaceutical sector.
|
Mr James S McBrayer | Chief Executive OfficerManaging DirectorCompany Secretary | Jun 2008 |
Mr McBrayer has more than 30 years experience in nuclear medicine and is a trained Nuclear Pharmacist. Mr McBrayer held the role of Managing Director at Lipa Pharmaceuticals. Mr McBrayer has been a member of the Board since 3 June 2008 at which time he accepted the role of Managing Director.
|
Mr Kevin Michael John Barrow | Non-Executive Director | Sep 2022 |
Mr Barrow was appointed to the Board on 1 September 2022. He has more than 20 years of experience in the healthcare industry, which includes numerous governance and senior executive roles.
|
Mr Gregory George King | Non-Executive Director | Sep 2022 |
Mr King has over 25 years' experience as a clinician, educator and researcher to the Cyclopharm board. He is also the Staff Specialist in the Department of Respiratory Medicine at Royal North Shore Hospital, where he directs the asthma service and is the Medical Director of the Respiratory Investigation Unit, and the Research Leader of the Airway Physiology and Imaging Group at the Woolcock Institute of Medical Research.
|
Mr John Wigglesworth | Non-Executive Director | Feb 2024 |
Mr Wigglesworth brings with him 37 years of professional experience, including nearly 25 years as a Partner at KPMG. His background as a Chartered Accountant and Company Director, coupled with his industry experience. Mr Wigglesworths career include a company director having held several previous Board positions over the past decade including Atlas Arteria Limited (ASX:ALX) and also in public sector health entities, While at KPMG John advised and supported many Australian and international multinational companies during periods of international growth., Held various KPMG leadership positions including serving as a member of the Audit Leadership Group and National leader of KPMG Audits Retention & Conversion function, managing proposals, client relationship management, and global management groups/committees, Expertise in ASX listing readiness, IPOs, and business transition, working closely with companies navigating the challenges of transitioning to a listed entity, Financial reporting and market communications, on ASX and regulatory reporting along with financial reporting matters. He has experience in risk management, including Cyber, and serving as Chairman of the Audit & Risk Committee at both Atlas Arteria Limited and Macquarie University.
|
Mathew Farag | Chief Operating Officer |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Anglo Australian Christian and Charitable Fund | 13,211,332 | 14.20% |
Barings Acceptance Limited | 11,444,962 | 12.30% |
HSBC Custody Nominees (Australia) Limited A/C 2 | 10,023,994 | 10.77% |
National Nominees Limited | 9,732,155 | 10.46% |
Chemical Overseas Limited (i) | 8,005,769 | 8.60% |
CVC Limited | 6,644,758 | 7.14% |
Citicorp Nominees Pty Limited | 3,524,128 | 3.79% |
McBrayer Reid Investments Pty Ltd - LTIP 6 | 1,721,554 | 1.85% |
UBS Nominees Pty Ltd | 1,565,665 | 1.68% |
Chemical Overseas Limited (ii)\ | 1,182,239 | 1.27% |
Phillips River Pty Ltd <GAT AC> | 1,038,914 | 1.12% |
Lloyds & Casanove Investment Partners Ltd | 987,503 | 1.06% |
Mr James McBrayer (i) | 861,728 | 0.92% |
Mr James McBrayer (ii) | 861,728 | 0.92% |
South Seas Holdings Pty Limited | 686,538 | 0.74% |
City & Westminster Limited | 556,327 | 0.60% |
Mathew Farag <LTIP Account Holding 4> | 500,000 | 0.54% |
McBrayer Reid Investments Pty Limited | 500,000 | 0.54% |
Brispot Nominees Pty Ltd | 453,202 | 0.49% |
Malackey Holdings Pty Ltd | 431,758 | 0.46% |